Literature DB >> 24639230

Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines.

Suresh B Boppana1, William J Britt.   

Abstract

The development of prophylactic and to lesser extent therapeutic vaccines for the prevention of disease associated with human cytomegalovirus (HCMV) infections has received considerable attention from biomedical researchers and pharmaceutical companies over the previous 15 years, even though attempts to produce such vaccines have been described in the literature for over 40 years. Studies of the natural history of congenital HCMV infection and infection in allograft recipients have suggested that prophylaxis of disease associated with HCMV infection could be possible, particularly in hosts at risk for more severe disease secondary to the lack of preexisting immunity. Provided a substantial understanding of immune response to HCMV together with several animal models that faithfully recapitulate aspects of human infection and immunity, investigators seem well positioned to design and test candidate vaccines. Yet more recent studies of the role of a maternal immunity in the natural history of congenital HCMV infection, including the recognition that reinfection of previously immune women by genetically distinct strains of HCMV occur in populations with a high seroprevalence, have raised several questions about the nature of protective immunity in maternal populations. This finding coupled with observations that have documented a significant incidence of damaging congenital infections in offspring of women with immunity to HCMV prior to conception has suggested that vaccine development based on conventional paradigms of adaptive immunity to viral infections may be of limited value in the prevention of damaging congenital HCMV infections. Perhaps a more achievable goal will be prophylactic vaccines to modify HCMV associated disease in allograft transplant recipients. Although recent descriptions of the results from vaccine trials have been heralded as evidence of an emerging success in the quest for a HCMV vaccine, careful analyses of these studies have also revealed that major hurdles remain to be addressed by current strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24639230     DOI: 10.1007/978-1-62703-788-4_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

Authors:  Lawrence M Kauvar; Keyi Liu; Minha Park; Neal DeChene; Robert Stephenson; Edgar Tenorio; Stote L Ellsworth; Takako Tabata; Matthew Petitt; Mitsuru Tsuge; June Fang-Hoover; Stuart P Adler; Xiaohong Cui; Michael A McVoy; Lenore Pereira
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 2.  The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.

Authors:  A Louise McCormick; Edward S Mocarski
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

Review 3.  Advances in the prevention and treatment of congenital cytomegalovirus infection.

Authors:  Scott H James; David W Kimberlin
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

4.  Murine CMV-induced hearing loss is associated with inner ear inflammation and loss of spiral ganglia neurons.

Authors:  Russell D Bradford; Young-Gun Yoo; Mijo Golemac; Ester Pernjak Pugel; Stipan Jonjic; William J Britt
Journal:  PLoS Pathog       Date:  2015-04-13       Impact factor: 6.823

5.  Increased Cytomegalovirus Secretion and Risks of Infant Infection by Breastfeeding Duration From Maternal Human Immunodeficiency Virus Positive Compared to Negative Mothers in Sub-Saharan Africa.

Authors:  Kunda G Musonda; Mary Nyonda; Suzanne Filteau; Lackson Kasonka; Mwaka Monze; Ursula A Gompels
Journal:  J Pediatric Infect Dis Soc       Date:  2016-04-21       Impact factor: 3.164

6.  Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.

Authors:  D N Streblow; Y K Hwee; C N Kreklywich; T Andoh; M Denton; P Smith; E Hart; R Broekel; C Pallett; K Rogers; A D Streblow; M Chuop; A Perry; M Slifka; I Messaoudi; S L Orloff
Journal:  Am J Transplant       Date:  2015-03-12       Impact factor: 8.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.